Pα+ Psychedelic Bulletin #208: CEOs' FDA wish list, APA Division 56 leader on psychedelics, Compass PTSD results, Cybin CEO change

Pα+ Psychedelic Bulletin #208 compiles updates and conference conversations spanning FDA policy, professional psychology perspectives, clinical progress, and company leadership. The bulletin highlights a “Psychedelic CEOs' FDA Wish-List” conversation between Compass CEO Kabir Nath and (then) Cybin CEO Doug Drysdale, moderated by Amy Emerson, focused on regulatory clarity, REMS constraints, label expansion, and aligning training programs across molecules and indications. It also features Jessica Punzo, President of the APA Trauma Psychology Division, discussing how psychologists engage with psychedelics. On clinical and corporate fronts, it notes Compass publishing its Phase 2 PTSD study update, MindMed publishing a Phase 2b LSD study for GAD, and Cybin removing Doug Drysdale as CEO, plus additional items including DoD testing psilocybin for military use.